Skip to main content
Premium Trial:

Request an Annual Quote

Berkeley HeartLab Wins CAP Accreditation

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Celera subsidiary Berkeley HeartLab said today that it has received accreditation from the College of American Pathologists (CAP) for its CLIA-registered lab.

Based in Alameda, Calif., Berkeley HeartLab provides testing services for predicting cardiovascular risk and patient treatment management.

The US Centers for Medicare and Medicaid Services has granted CAP's Laboratory Accreditation Program the authority to inspect and accredit labs for requirements of many US states.

"This is an important achievement for our laboratory as we continue to provide advanced lipid and cardiovascular genetic testing to our physicians and the patients they serve," Jean Wilson, Berkeley HeartLab's VP of laboratory operations, said in a statement.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.